{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/management/adults-hiv-positive/","result":{"pageContext":{"chapter":{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)","depth":2,"htmlHeader":"<!-- begin field bec3f410-b4f0-4f1f-a05e-18d385f1ac6d --><h2>Scenario: Adults (HIV positive)</h2><!-- end field bec3f410-b4f0-4f1f-a05e-18d385f1ac6d -->","summary":"Covers the management of oral candidiasis in adults who are HIV-positive.","htmlStringContent":"<!-- begin item 5e964d59-e18c-4d67-8022-a09202c4e059 --><!-- begin field 0d5aab3e-5cdc-4c70-9063-acbd00879c7e --><p>From age 18 years onwards.</p><!-- end field 0d5aab3e-5cdc-4c70-9063-acbd00879c7e --><!-- end item 5e964d59-e18c-4d67-8022-a09202c4e059 -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"4f036110-5083-5cff-8fb8-70ceb430e051","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field b472f1ff-6faa-42ec-914a-e7d0ce7a9976 --><h3>How should I manage an adult with oral candidiasis who is HIV positive?</h3><!-- end field b472f1ff-6faa-42ec-914a-e7d0ce7a9976 -->","summary":null,"htmlStringContent":"<!-- begin item de06f7a0-fa22-4ccd-b77a-4997ea192a2b --><!-- begin field 50314bed-9f0d-4a5b-89b4-beec6b36238d --><p><strong>Admit the person if:</strong></p><ul><li>There is evidence of <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">systemic illness</a> (candidaemia).</li><li>There is widespread infection (such as oesophageal candidiasis, characterized by difficulty or pain on swallowing, or retrosternal pain).<ul><li>Lower the threshold for admission in people who are markedly immunocompromised.</li></ul></li></ul><p><strong>If the person can be managed in primary care:</strong></p><ul><li><strong>Prescribe oral fluconazole 100 mg for 7 days provided </strong>the person is otherwise well and is not taking prophylactic antimycotic treatment.</li><li><strong>Seek specialist advice <em>before</em> starting treatment </strong><strong>if:</strong><ul><li>Oral candidiasis is extensive or severe.</li><li>Treatment with fluconazole for a previous episode of candidiasis was ineffective.</li></ul></li><li><strong>Give appropriate lifestyle advice. </strong>In particular:<ul><li>Advise on good dental hygiene.</li><li>If the person is a smoker, offer advice on smoking cessation. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for detailed information.</li><li>If the person is using an inhaled corticosteroid, advise the following: good inhaler technique; rinsing the mouth with water (or cleaning the teeth) after inhalation, to remove any drug particles; using a spacer device to reduce the impaction of particles in the oral cavity; and stepping down the dose of inhaled corticosteroid when appropriate.<ul><li>See the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/management/corticosteroids-inhaled/#minimizing-adverse-effects\">Minimizing&nbsp;the risks of adverse effects</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/\">Corticosteroids - inhaled</a> for more information. </li></ul></li><li>If the person wears dentures, advise them to:<ul><li>Leave the dentures out for at least 6 hours in each 24-hour period to promote healing of the gums. If the gums are inflamed, they may benefit from the dentures being left out for longer.</li><li>Clean dentures by brushing and then soaking them in a disinfectant solution (for example chlorhexidine or hexetidine) overnight. The dentures can be soaked in any solution marketed to sterilize baby's bottles (providing the dentures contain no metal).</li><li>Allow the dentures to air-dry after disinfection — this also kills adherent<em> Candida</em>.</li><li>Brush the mucosal surface regularly with a soft brush.</li><li>See a dentist to correct ill-fitting dentures.</li></ul></li><li>If the person has diabetes,<strong> </strong>review diabetic control and manage accordingly, particularly if there are recurrent episodes of oral candidiasis. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for detailed information.<ul><li>For people taking a sulphonylurea (such as gliclazide), be aware of drug interactions with <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/miconazole-oral-gel/\">miconazole</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/#drug-interactions\">fluconazole</a>.</li></ul></li></ul></li><li><strong>Review the person after 7 days. </strong><ul><li>If the infection has not completely resolved, consider the following: extend the course of fluconazole for a further 7 days (refer to an oral surgeon if the infection persists after this); swab to identify the causative organism; seek specialist advice; or refer to an oral surgeon.</li><li>Use clinical judgement, taking into account the severity of infection (there should be a low threshold for early referral if infection is severe), the level of immunocompromise, and the response to treatment. </li></ul></li><li><strong>Also consider referring to an oral surgeon (or seeking specialist advice) if:</strong><ul><li>The person has breakthrough candidiasis while taking preventive treatment (this may indicate candidal resistance).</li><li>The person has recurrent episodes of oral candidiasis.</li><li>There is doubt about the diagnosis. </li></ul></li><li><strong>Consider referring for biopsy</strong> people with <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/diagnosis/diagnosis/\">chronic plaque-like oral candidiasis</a> that is unresponsive to treatment, as it carries a risk of malignancy.</li></ul><!-- end field 50314bed-9f0d-4a5b-89b4-beec6b36238d --><!-- end item de06f7a0-fa22-4ccd-b77a-4997ea192a2b -->","subChapters":[{"id":"c28d120f-4b88-532a-81f4-94d5a59b6655","slug":"basis-for-recommendation-fe6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field adaada1c-1e42-4d5a-b3db-2108f18470ad --><h4>Basis for recommendation</h4><!-- end field adaada1c-1e42-4d5a-b3db-2108f18470ad -->","summary":null,"htmlStringContent":"<!-- begin item fe6d8382-48e6-4f33-aa67-302e147ded02 --><!-- begin field 5e24a6f3-5dc0-47de-8b81-b1671bd3e4ab --><p>These recommendations are based on expert opinion in the <em>Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>], the World Health Organization (WHO) <em>Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">WHO, 2014</a>], the<em> </em>Scottish Dental Clinical Effectiveness Programme (SDCEP) guideline <em>Management of acute dental problems: Guidance for healthcare professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">SDCEP, 2013</a>]<em>, </em>the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>], review articles on oral infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Ellepola and Samaranayake, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Akpan and Morgan, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Gonsalves et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Garcia-Cuesta, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Patil, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BMJ, 2017</a>], and a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hay and Ashbee, 2010</a>].</p><h5>Admission</h5><ul><li>This recommendation is based on the fact that systemic/invasive candidiasis is a significant cause of morbidity and mortality, especially in people who are immunocompromised. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">Complications</a> for more information.</li></ul><h5>Antifungal treatment</h5><ul><li><strong>Fluconazole has a broad range of antifungal activity,</strong> including against <em>Candida</em> species [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>]. It is systemically absorbed, which is an advantage for widespread candidal infection.</li><li>For HIV-positive adults with oral candidiasis, the WHO guideline recommends oral fluconazole 100–150 mg for 7–14 days as the preferred treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">WHO, 2014</a>]. The BNF recommends 50 mg daily (100 mg daily in unusually difficult infections) given for 7–14 days in oropharyngeal candidiasis (maximum of 14 days except in severely immunocompromised people) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>].</li><li>Evidence from a Cochrane systematic review (search date: July 2009) that investigated the effectiveness of interventions for both the prevention and treatment of oral candidiasis in children and adults with HIV (n = 3445) showed that fluconazole is more effective than nystatin, and is effective at preventing candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pienaar et al, 2010</a>].</li><li>Expert opinion in guidelines and a review article is that systemic antifungals may be necessary for people with moderate to severe disease and people who are immunocompromised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">SDCEP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Patil, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>].</li></ul><h5>Lifestyle advice</h5><ul><li>These recommendations are based on the fact that poor dental hygiene, inhaled corticosteroids, the use of dentures, smoking, and diabetes are also risk factors for oral candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/causes-risk-factors/\">Risk factors</a> for more information.<ul><li>In addition for dentures:<ul><li>Expert opinion in review articles is that chlorhexidine is an antiseptic with a broad-spectrum activity, including antimycotic activity against <em>Candida</em> species. It can be used as an effective disinfectant for dentures, and it inhibits adhesion of <em>Candida</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Ellepola and Samaranayake, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Garcia-Cuesta, 2014</a>].</li><li>A small, open-label, comparative RCT in 61 people found that twice-daily rinses with the antiseptic hexetidine resulted in a significant reduction in the amount of <em>C. albicans </em>present in saliva, compared with pretreatment levels (no control group was included) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Koray et al, 2005</a>].</li><li>Expert opinion in a guideline is that for the management of denture-related candidiasis, disinfection of the denture, in addition to antifungal treatment, is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>].</li></ul></li><li>In addition for diabetes, most experts agree that good control of blood glucose is important in the long-term management of oral candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Soysa et al, 2006</a>]. This will also have other wide-reaching benefits.</li></ul></li></ul><h5>Follow up and managing treatment failure</h5><ul><li>Oral candidiasis is a serious cause of <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">morbidity and mortality</a> in people who are immunosuppressed, and it is reasonable to ensure treatment has been satisfactory and complications have not developed.</li><li>Expert opinion in a review article is that if initial treatment is not fully effective, extending treatment duration is a reasonable option before expert advice or referral are sought, provided deterioration has not occurred [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>]. CKS recommends using clinical judgement to decide whether to give another course of fluconazole, swab to identify the causative organism, seek specialist advice, or refer to secondary care, taking into account the severity of infection, the level of immunocompromise, and the response to treatment. <ul><li>The recommendation to consider swabbing is based on expert opinion in a review article, which states that microbiological techniques are required when the clinical diagnosis needs to be confirmed, for establishing a differential diagnosis, and in cases characterized by resistance to antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>].</li></ul></li></ul><h5>Referral or seeking specialist advice</h5><ul><li>The BNF recommends referral for investigation if candidal infection fails to respond to 1–2 weeks of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. Other referral criteria are based on what CKS considers to be good clinical practice. </li><li>Expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Singh, 2014</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>] is that biopsies are indicated in people with hyperplastic candidiasis, due to the increased risk of malignancy.</li></ul><h5>Treatments not recommended </h5><ul><li><strong>Topical antifungals</strong> are not recommended because evidence from randomized controlled trials suggests they are not as effective as systemic drugs for the treatment of oropharyngeal candidiasis associated with HIV infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pienaar et al, 2010</a>].</li><li><strong>Miconazole mucoadhesive buccal tablets </strong>are licensed for the treatment of oropharyngeal candidiasis in immunocompromised people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. However, they are considerably more expensive than miconazole oral gel and are not currently recommended by the Scottish Medicines Consortium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Scottish Medicines Consortium, 2011</a>]. For these reasons, CKS does not recommend its use in primary care.</li><li><strong>Oral itraconazole </strong>should be reserved for cases of fluconazole-resistant candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. Specialist advice should be obtained before initiating itraconazole therapy because of the increased risk of drug interactions and adverse effects.</li><li><strong>Oral ketoconazole </strong>should no longer be prescribed for the treatment of fungal infections as the risk of liver damage outweighs the benefits. For this reason, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has suspended its marketing authorisation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">MHRA, 2013</a>]. See the <a href=\"http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON297530\" data-hyperlink-id=\"4292f9da-0391-476d-9cfe-a99201317958\">MHRA website</a> for more information.</li><li><strong>Oral amphotericin </strong>is not recommended as there is a lack of trial evidence of efficacy in the treatment of oral candidiasis. It is sometimes used as an adjunct to other systemic antimycotic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>].</li></ul><!-- end field 5e24a6f3-5dc0-47de-8b81-b1671bd3e4ab --><!-- end item fe6d8382-48e6-4f33-aa67-302e147ded02 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}